EBSAM
ABEO icon

Eubel Brady & Suttman Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4
Closed – – 73
2021
Q2 		$0 Buy
+4
New +$163 ﹤0.01% 651

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's ABEO Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Abeona Therapeutics (ABEO) in Q3 2021, closing a stake of 4 shares.

Eubel Brady & Suttman Asset Management first reported a position in ABEO in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 58 funds tracked by Wall St. Rank hold ABEO as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Abeona Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 4 Abeona Therapeutics shares in Q3 2021.
  • Eubel Brady & Suttman Asset Management first reported a position in Abeona Therapeutics in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Abeona Therapeutics position peaked at $0 in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.